Our study aimed to determine the predictive value of GFAP for longitudinal cognitive deterioration and trends in CSF biomarkers, while Bartl assessed whether the biomarker panel (NTK) that has been validated in AD can be equally established in the PD cohort. This evidence concerns the gene GFAP and Parkinson disease.